Ionis Pharmaceuticals, Inc.
IONS
$72.33
-$0.01-0.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.83% | 20.41% | 16.05% | -7.64% | -10.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.83% | 20.41% | 16.05% | -7.64% | -10.48% |
| Cost of Revenue | 2.06% | -3.23% | -2.80% | -2.96% | 0.44% |
| Gross Profit | 105.87% | 161.44% | 147.11% | -21.43% | -71.42% |
| SG&A Expenses | 47.25% | 52.67% | 32.62% | 32.46% | 25.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.30% | 7.94% | 4.50% | 3.84% | 5.25% |
| Operating Income | 19.66% | 20.64% | 22.75% | -28.00% | -42.36% |
| Income Before Tax | 17.49% | 27.28% | 22.15% | -27.60% | -37.76% |
| Income Tax Expenses | 128.95% | -179.00% | -146.95% | -129.17% | -119.10% |
| Earnings from Continuing Operations | 15.97% | 28.56% | 26.67% | -19.04% | -23.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.97% | 28.56% | 26.67% | -19.04% | -23.92% |
| EBIT | 19.66% | 20.64% | 22.75% | -28.00% | -42.36% |
| EBITDA | 20.27% | 21.05% | 23.22% | -29.36% | -44.33% |
| EPS Basic | 22.06% | 33.96% | 30.58% | -11.81% | -18.79% |
| Normalized Basic EPS | 20.91% | 26.65% | 27.11% | -24.58% | -40.45% |
| EPS Diluted | 19.54% | 30.83% | 27.55% | -11.81% | -18.79% |
| Normalized Diluted EPS | 17.21% | 21.68% | 22.12% | -24.58% | -40.45% |
| Average Basic Shares Outstanding | 6.95% | 8.83% | 7.89% | 6.13% | 4.35% |
| Average Diluted Shares Outstanding | 10.82% | 12.80% | 11.89% | 6.13% | 4.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |